Trials / Terminated
TerminatedNCT00040157
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3TC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACH126-443 (Beta-L-Fd4C) |
Timeline
- Completion
- 2003-05-01
- First posted
- 2002-06-25
- Last updated
- 2015-12-30
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00040157. Inclusion in this directory is not an endorsement.